Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62,327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Zhang P, Shi S, Xu J, Chen Z, Song L, Zhang X, Cheng Y, Zhang Y, Ye F, Li Z, Yin F, Ji D, Gao H, Li Y, Chen W, Yang M, Weng D, Wu C, Ma Y, Sheng W, Zhao Y, Yin X, Shen W, Su W, Shi M, Fan S, Tan P, Xu Q, Lu M, Shen L. Zhang P, et al. Among authors: xu q, xu j. Eur J Cancer. 2024 Mar;199:113539. doi: 10.1016/j.ejca.2024.113539. Epub 2024 Jan 15. Eur J Cancer. 2024. PMID: 38237373 Free article. Clinical Trial.
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Cheng AL, et al. Among authors: xu j. Eur J Cancer. 2012 Jul;48(10):1452-65. doi: 10.1016/j.ejca.2011.12.006. Epub 2012 Jan 10. Eur J Cancer. 2012. PMID: 22240282 Clinical Trial.
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H. Li J, et al. Among authors: xu n, xu j. J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585. Epub 2013 Aug 5. J Clin Oncol. 2013. PMID: 23918952 Clinical Trial.
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, Guan ZZ, Qin SK, Wang JJ, Yu SY, Wang YJ, Jin YN, Tao M, Zheng LZ, Pan LX. Shen L, et al. Among authors: xu jm. Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):295-300. doi: 10.3760/cma.j.issn.0253-3766.2013.04.012. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 23985260 Clinical Trial. Chinese.
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Shen L, et al. Among authors: xu r, xu j. Gastric Cancer. 2015 Jan;18(1):168-76. doi: 10.1007/s10120-014-0351-5. Epub 2014 Feb 21. Gastric Cancer. 2015. PMID: 24557418 Free PMC article. Clinical Trial.
S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Ge F, Xu N, Bai Y, Ba Y, Zhang Y, Li F, Xu H, Jia R, Wang Y, Lin L, Xu J. Ge F, et al. Among authors: xu n, xu h, xu j. Oncologist. 2014 Nov;19(11):1133-4. doi: 10.1634/theoncologist.2014-0223. Epub 2014 Oct 1. Oncologist. 2014. PMID: 25273077 Free PMC article. Clinical Trial.
62,327 results
You have reached the last available page of results. Please see the User Guide for more information.